Press releases

Release
02.09.2019

Additional positive results from the Phase IIA clinical study on VALEDIA® in lipid metabolism and arterial hypertension

Download
Release
30.08.2019

2019 half-year report and update on key achievements (in French)

Download
Release
01.08.2019

Provision of the Registration Document (R 19-030) and Statement of cash position as of June 30, 2019 (in French)

Download
Release
26.07.2019

Half year report of the liquidity contract – July 2019 (in French)

Download
Release
03.07.2019

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®, now the first product proven effective in people with prediabetes

Download
Release
24.06.2019

VALBIOTIS participates in the first HealthTech Investor Days, organized by France Biotech

Download
Release
07.06.2019

VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention at the 2019 scientific sessions of the American Diabetes Association

Download
Release
28.05.2019

VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group

Download
Release
14.05.2019

VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA® before 31 July 2019

Download